Evidence map›Paper›PMID 37762524›Full record

ArticleInternational journal of molecular sciences2023

A Paratope-Enhanced Method to Determine Breadth and Depth TCR Clonal Metrics of the Private Human T-Cell Vaccine Response after SARS-CoV-2 Vaccination.

Dalin Li, Ana Jimena Pavlovitch-Bedzyk, Joseph E Ebinger, Abdul Khan, Mohamed Hamideh, Akil Merchant, Jane C Figueiredo, Susan Cheng, Mark M Davis, Dermot P B McGovern and 3 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dalin LiInflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Ana Jimena Pavlovitch-BedzykComputational and Systems Immunology Program, Stanford University School of Medicine, Stanford, CA 94305, USA.
Joseph E EbingerDepartment of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.ORCID 0000-0002-0587-1572
Abdul KhanInflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Mohamed HamidehInflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Akil MerchantCedars-Sinai Cancer and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.ORCID 0000-0001-7472-822X
Jane C FigueiredoCedars-Sinai Cancer and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Susan ChengDepartment of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.ORCID 0000-0002-4977-036X
Mark M DavisComputational and Systems Immunology Program, Stanford University School of Medicine, Stanford, CA 94305, USA.
Dermot P B McGovernInflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Gil Y MelmedInflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.ORCID 0000-0002-2591-5165
Alexander M XuCedars-Sinai Cancer and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.ORCID 0000-0003-4877-4358
Jonathan BraunInflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.ORCID 0000-0003-1646-2974

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Using polygenic scores to enhance both variant discovery, and understanding of functional consequences of genetic variation in IBD.P01DK046763 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI MCGOVERN, DERMOT PATRICK · 1992 to 2020
$31.1M
Utilizing the Phenomics of IBD to Enhance Gene DiscoveryU01DK062413 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI Dermot Patrick McGovern · 2002 to 2026
$12.2M
Diversity and Determinants of the Immune-Inflammatory Response to SARS-CoV-2U54CA260591 · NCI · CEDARS-SINAI MEDICAL CENTER · PI FIGUEIREDO, JANE C., KARIN, MICHAEL · 2020 to 2024
$9.1M
NCATS NIH HHS UL1 TR001881NCATS NIH HHS UL1TR001881NCI NIH HHS U54 CA260591NIDDK NIH HHS P01 DK046763NIDDK NIH HHS P01DK046763NIDDK NIH HHS U01 DK062413NIDDK NIH HHS U01DK062413
6 · The paper itself

Abstract

Quantitative metrics for vaccine-induced T-cell responses are an important need for developing correlates of protection and their use in vaccine-based medical management and population health. Molecular TCR analysis is an appealing strategy but currently requires a targeted methodology involving complex integration of ex vivo data (antigen-specific functional T-cell cytokine responses and TCR molecular responses) that uncover only public antigen-specific metrics. Here, we describe an untargeted private TCR method that measures breadth and depth metrics of the T-cell response to vaccine challenge using a simple pre- and post-vaccine subject sampling, TCR immunoseq analysis, and a bioinformatic approach using self-organizing maps and GLIPH2. Among 515 subjects undergoing SARS-CoV-2 mRNA vaccination, we found that breadth and depth metrics were moderately correlated between the targeted public TCR response and untargeted private TCR response methods. The untargeted private TCR method was sufficiently sensitive to distinguish subgroups of potential clinical significance also observed using public TCR methods (the reduced T-cell vaccine response with age and the paradoxically elevated T-cell vaccine response of patients on anti-TNF immunotherapy). These observations suggest the promise of this untargeted private TCR method to produce T-cell vaccine-response metrics in an antigen-agnostic and individual-autonomous context.

Indexed as

COVID-19COVID-19 VaccinesBinding Sites, AntibodyCD8-Positive T-LymphocytesHumansReceptors, Antigen, T-CellSARS-CoV-2Tumor Necrosis Factor InhibitorsVaccinationCOVID-19 VaccinesReceptors, Antigen, T-CellTumor Necrosis Factor InhibitorsCDR3 domainsGLIPHSARS-CoV-2T-cell receptorsT-cells

Identifiers

PMID37762524
PMCPMC10531868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.